한글목차

세계의 의약품 수탁제조 시장 규모는 2035년에 CAGR 11.8%로 성장할 것으로 예측됩니다.

의약품 개발과 상업화에서 CMO의 역할 확대 :

의약품 수탁제조는 더 이상 대규모 의약품 제조에 국한되지 않고, 임상시험 생산에서 상업화에 이르기까지 의약품 개발의 전 과정에서 필수적인 역할을 하고 있습니다. 주요 CMO는 다음과 같은 종합적인 서비스를 제공합니다.

제제 개발: 제제 개발: 안정성, 생체 이용률, 환자 순응도 등 의약품 제제 최적화 관련 전문성

임상 제조: 임상시험용 임상시험용 의약품을 제조하고, GMP에 부합하는 공정 확보

약사 지원: 복잡한 세계 규제 요건에 대응하는 제약사 지원

공급망 관리: 전 세계 수요에 대응하기 위한 원활한 원료 조달, 생산, 유통 보장

복잡한 생물제제, 세포 및 유전자 치료제, 고활성 원료의약품(HPAPI)에 대한 수요가 증가함에 따라 CMO는 진화하는 업계의 요구에 대응하기 위해 역량을 확장하고 있습니다. 의약품의 신속한 승인과 세계 시장 진입을 촉진하는 CMO의 역할이 점점 더 중요해지고 있습니다.

의약품 위탁 생산의 진화: 산업 성장을 위한 전략적 필수 조건

세계 제약 산업은 혁신적인 의약품을 효율적으로 출시해야 하는 긴급한 필요성으로 인해 급격한 변화의 시기를 맞이하고 있습니다. 이러한 변화는 제약사의 운영 및 자본 지출을 줄이면서 생산 공정을 간소화하는 데 중요한 역할을 하는 CMO의 전략적 중요성을 높이고 있습니다. 의약품 개발 비용의 상승, 오리지널 의약품과 제네릭 의약품 수요 증가, 첨단 기술의 통합으로 인해 의약품 수탁제조 시장은 크게 확대될 태세를 갖추고 있습니다.

세계의 의약품 수탁제조 시장을 조사했으며, 시장 개요, 시장 성장에 대한 영향요인 및 시장 기회의 분석, 시장 규모 추이·예측, 각종 구분·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트 개요

제2장 개요

제3장 시장 개요

• 주요 조사 결과
• 시장 역학
• 영향 분석
  • 시장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
• 규제 프레임워크
• 신흥 시장과 메가트렌드
• Porter's Five Forces 분석
• PEST 분석
• SWOT 분석
• 업계에 영향을 미치는 주요 동향

제4장 의약품 수탁제조 시장 분석 : 서비스별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 의약품 제조 서비스
• 의약품 개발 서비스
• 바이오의약품 제조 서비스
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제5장 의약품 수탁제조 시장 분석 : 의약품 유형별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 브랜드약
• 제네릭 의약품
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제6장 의약품 수탁제조 시장 분석 : 최종사용자별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 대형 제약 기업
• 중소 규모 제약 기업
• 제네릭 의약품 기업
• 기타
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제7장 의약품 수탁제조 시장 분석 : 사업 규모별

• 주요 조사 결과
• 시장의 매력 지수
• 시장 규모 추이·예측
• 임상
• 상용
  • 시장 규모 추이·예측 : 지역별
  • 시장 점유율 : 지역별

제8장 의약품 수탁제조 시장 분석 : 지역별

• 주요 조사 결과
• 시장 규모 추이·예측

제9장 북미의 의약품 수탁제조 시장 분석

• 미국
• 캐나다

제10장 유럽의 의약품 수탁제조 시장 분석

• 독일
• 영국
• 프랑스
• 이탈리아
• 스페인
• 러시아
• 스위스
• 네덜란드
• 기타

제11장 아시아태평양의 의약품 수탁제조 시장 분석

• 일본
• 중국
• 인도
• 호주
• 한국
• 말레이시아
• 싱가포르
• 인도네시아
• 기타

제12장 라틴아메리카의 의약품 수탁제조 시장 분석

• 브라질
• 멕시코
• 아르헨티나
• 콜롬비아
• 기타

제13장 중동 및 아프리카의 의약품 수탁제조 시장 분석

• 남아프리카공화국
• 기타

제14장 기업 개요

• 경쟁 환경
• Lonza
• Catalent, Inc.
• Recipharm AB
• AbbVie Inc.
• Thermo Fisher Scientific Inc.
• Siegfried Holding AG
• Evonik Industries AG
• Boehringer Ingelheim International GmbH
• Piramal Pharma Solutions
• Samsung Biologics
• WuXi AppTec
• FUJIFILM Diosynth Biotechnologies
• ICON plc
• Abnova Corporation
• Vetter Pharma
• Aenova Group
• Almac Group
• Nipro Pharma Corporation
• Jubilant Pharmova Limited
• Pfizer Inc.
• Grifols, S.A.
• Charles River Laboratories
• IQVIA Inc.
• Baxter
• Curia Global, Inc.
• Lannett

제15장 결론·제안

• Visiongain의 결론
• 참여 기업에 대한 제안

영문목차

The global Pharmaceutical Contract Manufacturing market is projected to grow at a CAGR of 11.8% by 2035.

The Pharmaceutical Contract Manufacturing Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to understand the industry and its underlying dynamics better. It will also be helpful for companies that would like to expand into different sectors or expand their existing operations in a new region.

Expanding Role of CMOs in Drug Development & Commercialisation

The pharmaceutical contract manufacturing sector is no longer confined to large-scale drug production; it now plays an integral role in the entire drug development lifecycle, from clinical trial production to commercialisation. Leading CMOs provide comprehensive services, including:

Formulation Development: Expertise in optimising drug formulations for stability, bioavailability, and patient compliance.

Clinical Manufacturing: Production of investigational drugs for clinical trials, ensuring GMP-compliant processes.

Regulatory Support: Assisting pharmaceutical firms in navigating complex global regulatory requirements.

Supply Chain Management: Ensuring seamless raw material sourcing, production, and distribution to meet global demand.

As the demand for complex biologics, cell and gene therapies, and high-potency active pharmaceutical ingredients (HPAPIs) rises, CMOs are expanding their capabilities to meet evolving industry needs. Their role in facilitating faster drug approvals and global market access is becoming increasingly vital.

The Evolution of Pharmaceutical Contract Manufacturing: A Strategic Imperative for Industry Growth

The global pharmaceutical sector is undergoing rapid transformation, driven by the urgent need to efficiently bring innovative drugs to market. This shift has reinforced the strategic importance of Contract Manufacturing Organisations (CMOs), which play a crucial role in streamlining production processes while reducing pharmaceutical companies' operational and capital expenditures. With escalating drug development costs, increasing demand for both branded and generic medicines, and the integration of cutting-edge technologies, the pharmaceutical contract manufacturing market is poised for significant expansion.

What Questions Should You Ask Before Buying a Market Research Report?

• How is the pharmaceutical contract manufacturing market evolving?
• What is driving and restraining the pharmaceutical contract manufacturing market?
• How will each pharmaceutical contract manufacturing submarket segment grow over the forecast period, and how much revenue will these submarkets account for in 2035?
• How will the market shares for each pharmaceutical contract manufacturing submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading pharmaceutical contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035, and which geographical region will lead the market in 2035?
• Who are the leading players, and what are their prospects over the forecast period?
• What are the pharmaceutical contract manufacturing projects for these leading companies?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of pharmaceutical contract manufacturing projects now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the pharmaceutical contract manufacturing market?
• Where is the pharmaceutical contract manufacturing market heading, and how can you ensure you are at the forefront?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the pharmaceutical contract manufacturing market today and over the next 10 years:

• Our 355-page report provides you with 147 tables and 201 charts/graphs exclusively.
• The report highlights key lucrative areas in the industry so you can target them NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights the key successful trends, changes and revenue projections made by your competitors.
• Forecasts to 2035 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2035, our new study provides recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

• Services
• Pharmaceutical Manufacturing Services
• Drug Development Services
• Biologics Manufacturing Services
• Drug Type
• Branded
• Generics
• End-users
• Big Pharmaceutical Companies
• Small & Medium-sized Pharmaceutical Companies
• Generic Pharmaceutical Companies
• Other End-users
• Scale of Operation
• Clinical
• Commercial

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 27 leading national markets:

• North America
• U.S.
• Canada
• Europe
• GerU.Sy
• UK
• France
• Italy
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles of some of the leading companies in the Pharmaceutical Contract Manufacturing Market from 2025 to 2035, focusing on this segment of their operations.

• Leading companies and the potential for market growth
• AbbVie Inc.
• Abnova Corporation
• Aenova Group
• Almac Group
• Baxter
• Boehringer Ingelheim International GmbH
• Catalent, Inc.
• Charles River Laboratories
• Curia Global, Inc.
• Evonik Industries AG
• FUJIFILM Diosynth Biotechnologies
• Grifols, S.A.
• ICON plc
• IQVIA Inc.
• Jubilant Pharmova Limited
• Lannett
• Lonza
• Nipro Pharma Corporation
• Piramal Pharma Solutions
• Pfizer Inc.
• Recipharm AB
• Samsung Biologics
• Siegfried Holding AG
• Thermo Fisher Scientific Inc.
• Vetter Pharma
• WuXi AppTec

Overall world revenue for Pharmaceutical Contract Manufacturing Market, 2025 to 2035 in terms of value the market will surpass US$170 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organisations hold the most significant potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

• How will the Pharmaceutical Contract Manufacturing Market 2025 to 2035 report help you?
• In summary, our 350+ page report provides you with the following knowledge:
• Revenue forecasts to 2035 for Pharmaceutical Contract Manufacturing Market 2025 to 2035, with forecasts for services, drug type, end-users, and scale of operation, each estimated at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 27 key national markets - See forecasts for the Pharmaceutical Contract Manufacturing Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia, among other prominent economies.
• Prospects for established firms and those seeking to enter the market - including company profiles for 26 of the major companies involved in the Pharmaceutical Contract Manufacturing Market, 2025 to 2035.
• Find quantitative and qualitative analysis with independent predictions and invaluable business intelligence.

Table of Contents

1 Report Overview

• 1.1 Objectives of the Study
• 1.2 Introduction to Pharmaceutical Contract Manufacturing Market
• 1.3 What This Report Delivers
• 1.4 Why You Should Read This Report
• 1.5 Key Questions Answered by This Analytical Report Include:
• 1.6 Who is This Report For?
• 1.7 Methodology
  • 1.7.1 Market Definitions
  • 1.7.2 Market Evaluation & Forecasting Methodology
  • 1.7.3 Data Validation
    • 1.7.3.1 Primary Research
    • 1.7.3.2 Secondary Research
• 1.8 Frequently Asked Questions (FAQs)
• 1.9 Associated Visiongain Reports
• 1.10 About Visiongain

2 Executive Summary

3 Market Overview

• 3.1 Key Findings
• 3.2 Market Dynamics
• 3.3 Impact Analysis
  • 3.3.1 Market Driving Factors
    • 3.3.1.1 Patent Expiry and Increasing Demand for Generic Drugs
    • 3.3.1.2 Increasing Investments in Pharmaceutical R&D
    • 3.3.1.3 Investments in Advanced Manufacturing Technologies by CDMOs
  • 3.3.2 Market Restraining Factors
    • 3.3.2.1 Introduction of Serialization
    • 3.3.2.2 Varying Regulatory Scenarios
  • 3.3.3 Market Opportunities
    • 3.3.3.1 Increasing Demand for Biological Therapies
    • 3.3.3.2 Growth in the Nuclear Medicine Sector
    • 3.3.3.3 Growing Demand for Cell and Gene Therapies
    • 3.3.3.4 Growth Opportunities in Emerging Countries
• 3.4 Regulatory Framework
• 3.5 Emerging Markets and Megatrends
• 3.6 Porter's Five Forces Analysis
  • 3.6.1 Bargaining Power of Supplier
  • 3.6.2 Bargaining Power of Buyer
  • 3.6.3 Threat of New Entrants
  • 3.6.4 Threat of Substitutes
  • 3.6.5 Competitive Rivalry
• 3.7 PEST Analysis
• 3.8 SWOT Analysis
• 3.9 Key Trends Impacting the Industry
  • 3.9.1 Transition to Continuous Manufacturing
  • 3.9.2 Adoption of Single-use Systems in Biologics
  • 3.9.3 Integration of Digital Technologies
  • 3.9.4 Emphasis on Sustainability and Green Manufacturing
  • 3.9.5 Navigating Regulatory Challenges

4 Pharmaceutical Contract Manufacturing Market Analysis by Services

• 4.1 Key Findings
• 4.2 Services Segment: Market Attractiveness Index
• 4.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
• 4.4 Pharmaceutical Manufacturing Services
  • 4.4.1 Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • 4.4.2 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.4.3 Market Share by Region, 2025 & 2035 (%)
• 4.5 Drug Development Services
  • 4.5.1 Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • 4.5.2 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.5.3 Market Share by Region, 2025 & 2035 (%)
• 4.6 Biologics Manufacturing Services
  • 4.6.1 Market Forecast by Type, 2025-2035 (US$ Billion, AGR %)
  • 4.6.2 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 4.6.3 Market Share by Region, 2025 & 2035 (%)

5 Pharmaceutical Contract Manufacturing Market Analysis by Drug Type

• 5.1 Key Findings
• 5.2 Drug Type Segment: Market Attractiveness Index
• 5.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
• 5.4 Branded
  • 5.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 5.4.2 Market Share by Region, 2025 & 2035 (%)
• 5.5 Generics
  • 5.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 5.5.2 Market Share by Region, 2025 & 2035 (%)

6 Pharmaceutical Contract Manufacturing Market Analysis by End-users

• 6.1 Key Findings
• 6.2 End-users Segment: Market Attractiveness Index
• 6.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
• 6.4 Big Pharmaceutical Companies
  • 6.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.4.2 Market Share by Region, 2025 & 2035 (%)
• 6.5 Small & Medium-sized Pharmaceutical Companies
  • 6.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.5.2 Market Share by Region, 2025 & 2035 (%)
• 6.6 Generic Pharmaceutical Companies
  • 6.6.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.6.2 Market Share by Region, 2025 & 2035 (%)
• 6.7 Other End-users
  • 6.7.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 6.7.2 Market Share by Region, 2025 & 2035 (%)

7 Pharmaceutical Contract Manufacturing Market Analysis by Scale of Operation

• 7.1 Key Findings
• 7.2 Scale of Operation Segment: Market Attractiveness Index
• 7.3 Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 7.4 Clinical
  • 7.4.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.4.2 Market Share by Region, 2025 & 2035 (%)
• 7.5 Commercial
  • 7.5.1 Market Forecast by Region, 2025-2035 (US$ Billion, AGR %)
  • 7.5.2 Market Share by Region, 2025 & 2035 (%)

8 Pharmaceutical Contract Manufacturing Market Analysis by Region

• 8.1 Key Findings
• 8.2 Regional Market Size Estimation and Forecast

9 North America Pharmaceutical Contract Manufacturing Market Analysis

• 9.1 Key Findings
• 9.2 North America Pharmaceutical Contract Manufacturing Market Attractiveness Index
• 9.3 North America Pharmaceutical Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 9.4 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
• 9.5 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
• 9.6 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
• 9.7 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
• 9.8 North America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 9.9 U.S. Pharmaceutical Contract Manufacturing Market Analysis
• 9.10 Canada Pharmaceutical Contract Manufacturing Market Analysis

10 Europe Pharmaceutical Contract Manufacturing Market Analysis

• 10.1 Key Findings
• 10.2 Europe Pharmaceutical Contract Manufacturing Market Attractiveness Index
• 10.3 Europe Pharmaceutical Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 10.4 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
• 10.5 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
• 10.6 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
• 10.7 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
• 10.8 Europe Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 10.9 Germany Pharmaceutical Contract Manufacturing Market Analysis
• 10.10 UK Pharmaceutical Contract Manufacturing Market Analysis
• 10.11 France Pharmaceutical Contract Manufacturing Market Analysis
• 10.12 Italy Pharmaceutical Contract Manufacturing Market Analysis
• 10.13 Spain Pharmaceutical Contract Manufacturing Market Analysis
• 10.14 Russia Pharmaceutical Contract Manufacturing Market Analysis
• 10.15 Switzerland Pharmaceutical Contract Manufacturing Market Analysis
• 10.16 Netherlands Pharmaceutical Contract Manufacturing Market Analysis
• 10.17 Rest of Europe Pharmaceutical Contract Manufacturing Market Analysis

11 Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis

• 11.1 Key Findings
• 11.2 Asia Pacific Pharmaceutical Contract Manufacturing Market Attractiveness Index
• 11.3 Asia Pacific Pharmaceutical Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 11.4 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
• 11.5 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
• 11.6 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
• 11.7 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
• 11.8 Asia Pacific Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 11.9 Japan Pharmaceutical Contract Manufacturing Market Analysis
• 11.10 China Pharmaceutical Contract Manufacturing Market Analysis
• 11.11 India Pharmaceutical Contract Manufacturing Market Analysis
• 11.12 Australia Pharmaceutical Contract Manufacturing Market Analysis
• 11.13 South Korea Pharmaceutical Contract Manufacturing Market Analysis
• 11.14 Malaysia Pharmaceutical Contract Manufacturing Market Analysis
• 11.15 Singapore Pharmaceutical Contract Manufacturing Market Analysis
• 11.16 Indonesia Pharmaceutical Contract Manufacturing Market Analysis
• 11.17 Rest of Asia Pacific Pharmaceutical Contract Manufacturing Market Analysis

12 Latin America Pharmaceutical Contract Manufacturing Market Analysis

• 12.1 Key Findings
• 12.2 Latin America Pharmaceutical Contract Manufacturing Market Attractiveness Index
• 12.3 Latin America Pharmaceutical Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 12.4 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
• 12.5 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
• 12.6 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
• 12.7 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
• 12.8 Latin America Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 12.9 Brazil Pharmaceutical Contract Manufacturing Market Analysis
• 12.10 Mexico Pharmaceutical Contract Manufacturing Market Analysis
• 12.11 Argentina Pharmaceutical Contract Manufacturing Market Analysis
• 12.12 Colombia Pharmaceutical Contract Manufacturing Market Analysis
• 12.13 Rest of Latin America Pharmaceutical Contract Manufacturing Market Analysis

13 MEA Pharmaceutical Contract Manufacturing Market Analysis

• 13.1 Key Findings
• 13.2 MEA Pharmaceutical Contract Manufacturing Market Attractiveness Index
• 13.3 MEA Pharmaceutical Contract Manufacturing Market by Country, 2025, 2030 & 2035 (US$ Billion)
• 13.4 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Country
• 13.5 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Services
• 13.6 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Drug Type
• 13.7 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by End-users
• 13.8 MEA Pharmaceutical Contract Manufacturing Market Size Estimation and Forecast by Scale of Operation
• 13.9 GCC Pharmaceutical Contract Manufacturing Market Analysis
• 13.10 South Africa Pharmaceutical Contract Manufacturing Market Analysis
• 13.11 Rest of MEA Pharmaceutical Contract Manufacturing Market Analysis

14 Company Profiles

• 14.1 Competitive Landscape
• 14.2 Lonza
  • 14.2.1 Company Snapshot
  • 14.2.2 Company Overview
  • 14.2.3 Financial Analysis
    • 14.2.3.1 Net Revenue, 2019-2024
    • 14.2.3.2 R&D, 2019-2023
    • 14.2.3.3 Regional Market Shares, 2024
    • 14.2.3.4 Business Segment Market Shares, 2024
  • 14.2.4 Service Benchmarking
  • 14.2.5 Strategic Outlook
  • 14.2.6 SWOT Analysis
• 14.3 Catalent, Inc.
  • 14.3.1 Company Snapshot
  • 14.3.2 Company Overview
  • 14.3.3 Financial Analysis
    • 14.3.3.1 Net Revenue, 2019-2024
    • 14.3.3.2 Regional Market Shares, 2024
    • 14.3.3.3 Business Segment Market Shares, 2024
  • 14.3.4 Service Benchmarking
  • 14.3.5 Strategic Outlook
  • 14.3.6 SWOT Analysis
• 14.4 Recipharm AB
  • 14.4.1 Company Snapshot
  • 14.4.2 Company Overview
  • 14.4.3 Service Benchmarking
  • 14.4.4 Strategic Outlook
  • 14.4.5 SWOT Analysis
• 14.5 AbbVie Inc.
  • 14.5.1 Company Snapshot
  • 14.5.2 Company Overview
  • 14.5.3 Financial Analysis
    • 14.5.3.1 Net Revenue, 2019-2024
    • 14.5.3.2 R&D, 2019-2024
    • 14.5.3.3 Regional Market Shares, 2024
    • 14.5.3.4 Business Segment Market Shares, 2024
  • 14.5.4 Service Benchmarking
  • 14.5.5 SWOT Analysis
• 14.6 Thermo Fisher Scientific Inc.
  • 14.6.1 Company Snapshot
  • 14.6.2 Company Overview
  • 14.6.3 Financial Analysis
    • 14.6.3.1 Net Revenue, 2019-2024
    • 14.6.3.2 R&D, 2019-2024
    • 14.6.3.3 Regional Market Shares, 2023
    • 14.6.3.4 Business Segment Market Shares, 2023
  • 14.6.4 Service Benchmarking
  • 14.6.5 Strategic Outlook
  • 14.6.6 SWOT Analysis
• 14.7 Siegfried Holding AG
  • 14.7.1 Company Snapshot
  • 14.7.2 Company Overview
  • 14.7.3 Financial Analysis
    • 14.7.3.1 Net Revenue, 2019-2024
    • 14.7.3.2 Regional Market Shares, 2024
    • 14.7.3.3 Business Segment Market Shares, 2024
  • 14.7.4 Service Benchmarking
  • 14.7.5 Strategic Outlook
• 14.8 Evonik Industries AG
  • 14.8.1 Company Snapshot
  • 14.8.2 Company Overview
  • 14.8.3 Financial Analysis
    • 14.8.3.1 Net Revenue, 2019-2024
    • 14.8.3.2 Regional Market Shares, 2024
    • 14.8.3.3 Business Segment Market Shares, 2024
  • 14.8.4 Service Benchmarking
  • 14.8.5 Strategic Outlook
• 14.9 Boehringer Ingelheim International GmbH
  • 14.9.1 Company Snapshot
  • 14.9.2 Company Overview
  • 14.9.3 Financial Analysis
    • 14.9.3.1 Net Revenue, 2019-2023
    • 14.9.3.2 Regional Market Shares, 2023
    • 14.9.3.3 Business Segment Market Shares, 2023
  • 14.9.4 Service Benchmarking
• 14.10 Piramal Pharma Solutions
  • 14.10.1 Company Snapshot
  • 14.10.2 Company Overview
  • 14.10.3 Service Benchmarking
  • 14.10.4 Strategic Outlook
• 14.11 Samsung Biologics
  • 14.11.1 Company Snapshot
  • 14.11.2 Company Overview
  • 14.11.3 Financial Analysis
    • 14.11.3.1 Net Revenue, 2019-2024
  • 14.11.4 Service Benchmarking
  • 14.11.5 Strategic Outlook
• 14.12 WuXi AppTec
  • 14.12.1 Company Snapshot
  • 14.12.2 Company Overview
  • 14.12.3 Financial Analysis
    • 14.12.3.1 Net Revenue, 2019-2024
    • 14.12.3.2 Regional Market Shares, 2024
    • 14.12.3.3 Business Segment Market Shares, 2024
  • 14.12.4 Service Benchmarking
  • 14.12.5 Strategic Outlook
• 14.13 FUJIFILM Diosynth Biotechnologies
  • 14.13.1 Company Snapshot
  • 14.13.2 Company Overview
  • 14.13.3 Financial Analysis
    • 14.13.3.1 Net Revenue, 2019-2024
    • 14.13.3.2 R&D, 2019-2024
  • 14.13.4 Service Benchmarking
  • 14.13.5 Strategic Outlook
• 14.14 ICON plc
  • 14.14.1 Company Snapshot
  • 14.14.2 Company Overview
  • 14.14.3 Financial Analysis
    • 14.14.3.1 Net Revenue, 2019-2024
    • 14.14.3.2 Regional Market Shares, 2024
  • 14.14.4 Service Benchmarking
  • 14.14.5 Strategic Outlook
• 14.15 Abnova Corporation
  • 14.15.1 Company Snapshot
  • 14.15.2 Company Overview
  • 14.15.3 Service Benchmarking
  • 14.15.4 Strategic Outlook
• 14.16 Vetter Pharma
  • 14.16.1 Company Snapshot
  • 14.16.2 Company Overview
  • 14.16.3 Service Benchmarking
  • 14.16.4 Strategic Outlook
• 14.17 Aenova Group
  • 14.17.1 Company Snapshot
  • 14.17.2 Company Overview
  • 14.17.3 Financial Analysis
    • 14.17.3.1 Net Revenue, 2019-2023
    • 14.17.3.2 Regional Market Shares, 2023
    • 14.17.3.3 Business Segment Market Shares, 2023
  • 14.17.4 Service Benchmarking
  • 14.17.5 Strategic Outlook
• 14.18 Almac Group
  • 14.18.1 Company Snapshot
  • 14.18.2 Company Overview
  • 14.18.3 Service Benchmarking
  • 14.18.4 Strategic Outlook
• 14.19 Nipro Pharma Corporation
  • 14.19.1 Company Snapshot
  • 14.19.2 Company Overview
  • 14.19.3 Financial Analysis
    • 14.19.3.1 Net Revenue, 2019-2024
    • 14.19.3.2 R&D, 2019-2024
    • 14.19.3.3 Regional Market Shares, 2024
    • 14.19.3.4 Business Segment Market Shares, 2024
  • 14.19.4 Service Benchmarking
  • 14.19.5 Strategic Outlook
• 14.20 Jubilant Pharmova Limited
  • 14.20.1 Company Snapshot
  • 14.20.2 Company Overview
  • 14.20.3 Service Benchmarking
  • 14.20.4 Strategic Outlook
• 14.21 Pfizer Inc.
  • 14.21.1 Company Snapshot
  • 14.21.2 Company Overview
  • 14.21.3 Financial Analysis
    • 14.21.3.1 Net Revenue, 2019-2024
    • 14.21.3.2 R&D, 2019-2024
    • 14.21.3.3 Regional Market Shares, 2024
    • 14.21.3.4 Business Segment Market Shares, 2024
  • 14.21.4 Service Benchmarking
  • 14.21.5 Strategic Outlook
• 14.22 Grifols, S.A.
  • 14.22.1 Company Snapshot
  • 14.22.2 Company Overview
  • 14.22.3 Financial Analysis
    • 14.22.3.1 Net Revenue, 2019-2024
    • 14.22.3.2 R&D, 2019-2024
  • 14.22.4 Strategic Outlook
• 14.23 Charles River Laboratories
  • 14.23.1 Company Snapshot
  • 14.23.2 Company Overview
  • 14.23.3 Financial Analysis
    • 14.23.3.1 Net Revenue, 2019-2024
    • 14.23.3.2 Regional Market Shares, 2023
    • 14.23.3.3 Business Segment Market Shares, 2023
  • 14.23.4 Service Benchmarking
  • 14.23.5 Strategic Outlook
• 14.24 IQVIA Inc.
  • 14.24.1 Company Snapshot
  • 14.24.2 Company Overview
  • 14.24.3 Financial Analysis
    • 14.24.3.1 Net Revenue, 2019-2024
    • 14.24.3.2 Regional Market Shares, 2024
    • 14.24.3.3 Business Segment Market Shares, 2024
  • 14.24.4 Service Benchmarking
  • 14.24.5 Strategic Outlook
• 14.25 Baxter
  • 14.25.1 Company Snapshot
  • 14.25.2 Company Overview
  • 14.25.3 Financial Analysis
    • 14.25.3.1 Net Revenue, 2019-2024
    • 14.25.3.2 R&D, 2019-2024
    • 14.25.3.3 Regional Market Shares, 2023
    • 14.25.3.4 Business Segment Market Shares, 2023
  • 14.25.4 Service Benchmarking
• 14.26 Curia Global, Inc.
  • 14.26.1 Company Snapshot
  • 14.26.2 Company Overview
  • 14.26.3 Service Benchmarking
  • 14.26.4 Strategic Outlook
• 14.27 Lannett
  • 14.27.1 Company Snapshot
  • 14.27.2 Company Overview
  • 14.27.3 Service Benchmarking

15 Conclusion and Recommendations

• 15.1 Concluding Remarks from Visiongain
• 15.2 Recommendations for Market Players